These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 32836137)

  • 1. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
    Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
    Farkas Á; Jókay Á; Balásházy I; Füri P; Müller V; Tomisa G; Horváth A
    Eur J Pharm Sci; 2016 Oct; 93():371-9. PubMed ID: 27552906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of exhalation before the inhalation of dry powder aerosol drugs on the breathing parameters, emitted doses and aerosol size distributions.
    Farkas Á; Tomisa G; Kugler S; Nagy A; Vaskó A; Kis E; Szénási G; Gálffy G; Horváth A
    Int J Pharm X; 2023 Dec; 5():100167. PubMed ID: 36824288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of relationships between native and inhalation device specific spirometric parameters as a step towards patient tailored inhalation device selection.
    Farkas Á; Szipőcs A; Horváth A; Horváth I; Gálffy G; Varga J; Galambos K; Kugler S; Nagy A; Szalai Z
    Respir Med; 2019; 154():133-140. PubMed ID: 31252206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
    Altman P; Wehbe L; Dederichs J; Guerin T; Ament B; Moronta MC; Pino AV; Goyal P
    BMC Pulm Med; 2018 Jun; 18(1):100. PubMed ID: 29898702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro dose comparison of Respimat
    Ciciliani AM; Langguth P; Wachtel H
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1565-1577. PubMed ID: 28603412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real life dose emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort
    Bagherisadeghi G; Larhrib EH; Chrystyn H
    Int J Pharm; 2017 Apr; 522(1-2):137-146. PubMed ID: 28254655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.
    Chapman KR; Fogarty CM; Peckitt C; Lassen C; Jadayel D; Dederichs J; Dalvi M; Kramer B
    Int J Chron Obstruct Pulmon Dis; 2011; 6():353-63. PubMed ID: 21760722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of lung emptying before the inhalation of aerosol drugs on drug deposition in the respiratory system.
    Farkas Á; Tomisa G; Szénási G; Füri P; Kugler S; Nagy A; Varga J; Horváth A
    Int J Pharm X; 2023 Dec; 6():100192. PubMed ID: 37405278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the inhalation parameters of COPD patients through NEXThaler® and Ellipta® dry powder inhalers.
    Farkas Á; Horváth A; Réti I; Ilyés N; Havadtői B; Kovács T; Sánta B; Tomisa G; Czaun P; Gálffy G
    Respir Med; 2024 Apr; 224():107576. PubMed ID: 38403127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computer modeling of airway deposition distribution of Foster(®) NEXThaler(®) and Seretide(®) Diskus(®) dry powder combination drugs.
    Jókay Á; Farkas Á; Füri P; Horváth A; Tomisa G; Balásházy I
    Eur J Pharm Sci; 2016 Jun; 88():210-8. PubMed ID: 26976481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler.
    Abadelah M; Chrystyn H; Larhrib H
    Eur J Pharm Sci; 2019 Jun; 134():138-144. PubMed ID: 31005623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
    Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Satisfaction, preference and error occurrence of three dry powder inhalers as assessed by a cohort naïve to inhaler operation.
    Man KN; Tian Z; Lam DC; Wan JMF; Tan-Un KC
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1949-1963. PubMed ID: 29942127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation of Airway Deposition of an Aerosol Drug in COPD Patients.
    Farkas Á; Lizal F; Jedelsky J; Elcner J; Horváth A; Jicha M
    Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30939795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison.
    Broeders ME; Molema J; Burnell PK; Folgering HT
    J Aerosol Med; 2005; 18(1):74-82. PubMed ID: 15741776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Repeatability of Inspiration Performance Through Different Inhalers in Patients with Chronic Obstructive Pulmonary Disease and Control Volunteers.
    Erdelyi T; Lazar Z; Odler B; Tamasi L; Müller V
    J Aerosol Med Pulm Drug Deliv; 2020 Oct; 33(5):271-281. PubMed ID: 32460588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.